...that is critical to the share price. As well as being granted some form of accelerated approval.
Not so sure about that....good article in WSJ the other day regarding the short time span of Biotech bear markets. They traced all the Biotech collapses and rebounds. Bottom line, sell offs are severe but relatively short lived, and rebounds are equally severe.
...how bad will it be today? Because, man, it has been a one way trade to the downside that adds new meaning to the word brutal.
...fantastic post. I've been at it for 30 years, and agree that Markets have gotten extremely skewed, to a large degree because of the preponderance of Hedge Funds & to a lesser degree High Frequency Trading. But if your timeline is a few years for NVAX, the value will be realized as they will own the franchise on a multi $Billion RSV market.
...stock will go down ANOTHER 20%. Never seen anything like it....imagine where the stock price would be if they missed on ANY of their 5 successful trials!
Maybe the devastation in their share price gave them a wake call in terms of how they present to, and deal with, Wall Street. You can be sure that with the stock at YTD lows after multiple successful trials, they are hearing from some of their unhappy institutional investors.
....given the great anticipation of this data, the Press Release was bungled, and the share price has as a direct result suffered enormously.
...while we all rail against Piper's Tenthoff, its time to look at the quality of NVAX's press release re. the Maternal trial. Had NVAX simply put in to words what Greg Glenn stated during the Analyst Meeting and the subsequent Ladenburg Conference - that it is their belief that the data supports a finding of RSV protection out to at least 4 months - then maybe the share price wouldn't have collapsed 20+ %, and instead risen.
That would be a HUGE home run.......or any form of accelerated approval would be a very big boost for the stock.
NVAX should have released the data at least 24 hours ahead of the meeting and added more color to what they believed was the duration of efficacy. Greg Glenn said during the meeting and the Ladenburg Conference that he believed the data shows protection at least up to 4 months.
The next, and probably biggest, catalyst will be the November FDA meeting regarding the Phase 3 trial for Elderly. If they get a clean go ahead, its a boost. If they get it fast tracked its a BIG boost.
Greg Glenn said during the Analyst Meeting and the Ladenburg Thalmann Conference that RSV Maternal data showed protection up to 4 months, which would be a breakthrough success. Wall Street obviously feels otherwise.
Even without Maternal, which I believe they will garner revenue from, what is the revenue opportunity for Elderly? I understand this to be a far larger market.
Shocked at where the stock is given the 4 trials that have recently reported.